Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas | recruiting | Phase 2 | 27 | Mayo ClinicOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848750 | InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma | recruiting | — | 40 | Beijing Municipal Administration of HospitalsOTHER_GOV | 1 | Sep 30, 2026 |
| clinicaltrials |
| NCT06605664 | Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847710 | Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial(H-FROG) | recruiting | Phase 2 | 81 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00034216 | Collection of Blood From Patients With Cancer | recruiting | — | 1,750 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06726161 | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC(GPC3) | recruiting | Phase 1 / Phase 2 | 590 | RayzeBio, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07305428 | Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study | recruiting | N/A | 30 | The University of Hong KongOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06084234 | National Liver Cancer Screening Trial(TRACER) | recruiting | Phase 4 | 5,500 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06618664 | A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) | recruiting | Phase 3 | 590 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06737913 | HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma(HAIBrave-001) | recruiting | Phase 2 | 76 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07124000 | DESTINY-PANTUMOUR04(DP-04) | recruiting | — | 100 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07377487 | TheraSphere Japan Pre-Market Study(INDIGO) | recruiting | N/A | 51 | Boston Scientific CorporationINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841574 | HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC | recruiting | Phase 2 | 35 | Lianghe LuOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07839767 | Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence | recruiting | — | 20 | The University of Hong KongOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07840092 | Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma | recruiting | — | 500 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03981497 | Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms | recruiting | — | 500 | Francesco De CobelliOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06888063 | Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery(PUMP IV) | recruiting | Phase 2 | 40 | Erasmus Medical CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06915753 | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations(SURF431) | recruiting | Phase 1 | 125 | Tyra Biosciences, IncINDUSTRY | 4 | Sep 23, 2026 | clinicaltrials |
| NCT07291076 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | recruiting | Phase 1 / Phase 2 | 198 | Bristol-Myers SquibbINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07522476 | A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 30 | Virogin Biotech Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07832617 | Protoacoustic Imaging For 3D Mapping | recruiting | — | 24 | University of OklahomaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06375915 | Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy(PM-CARE) | recruiting | Phase 2 | 33 | Francesco De CobelliOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06929845 | Organoid Models of Hepatocellular Carcinoma | recruiting | N/A | 150 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07639138 | Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC | recruiting | Phase 2 | 32 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07793695 | Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma(ZINC-1LT/IOHCC) | recruiting | Phase 2 | 60 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830576 | Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation | recruiting | — | 205 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832006 | Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06954116 | Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence(CCGLC-017) | recruiting | Phase 2 | 26 | Tongji HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | recruiting | Early Phase 1 | 30 | University of ArizonaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07676383 | Precision Navigation to Improve Community Cancer Screening Participation | recruiting | N/A | 1,500 | Hunan Cancer HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02851784 | Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma | recruiting | Phase 2 / Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04409340 | Viscoelasticity Imaging to Assess Liver Cancer(VisCan) | recruiting | — | 200 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07027436 | Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.(DARTS) | recruiting | Phase 3 | 30 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824583 | A Study Evaluating a New Radiation Treatment Workflow (NGDS)(SPEED) | recruiting | N/A | 20 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06427941 | A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 630 | BeOne MedicinesINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT06007846 | A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer | recruiting | Phase 2 / Phase 3 | 12 | Inova Health Care ServicesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06263088 | EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. | recruiting | N/A | 200 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07044362 | Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis | recruiting | N/A | 100 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07776080 | Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07820644 | A Cohort Study (Risk Prediction of HCC in Patients With Chronic Liver Disease) | recruiting | — | 15,000 | Cai QingxianOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06674811 | Biomarkers of Resiliency In Childhood Cancer Surgery(BRICCS) | recruiting | — | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
Data updated 4 hours agoSource updated Sep 30, 2026source: clinicaltrials